Latest:
Personalizing Lung Cancer Treatment Reduces Toxicity and Improves Cure Rates
New lung cancer treatment options have emerged, and several groups are exploring treatment strategies that omit chemotherapy for locally advanced NSCLC.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Caroline Kozek, DNP, RN AGNP-C, OCN
Caroline Kozek, DNP, RN AGNP-C, OCN is an
Latest:
Dr Kozek on Oncology Nurses’ Perceived Difficulties in Providing Palliative Care to Adult Patients
Caroline Kozek, DNP, RN, AGNP-C, OCN, discusses a study assessing oncology nurses’ perceived difficulties in providing palliative care to adult patients.
Julie Lang, MD
Julie Lang, MD, is chief of Breast Surgery at the Lerner Research Institute and co-leader of the Breast Cancer Program at Cleveland Clinic.
Latest:
Dr Lang on Real-World Safety Data for Perioperative Pembrolizumab in Early TNBC
Julie Lang, MD, discusses real-world safety data from for the KEYNOTE-522 regimen in early triple-negative breast cancer.
Megan Kruse, MD
Megan Kruse, MD. Breast Medical Oncologist Director, Clinical Breast Cancer Research Cleveland Clinic.
Latest:
Dr Kruse on Long-Term Data for Adjuvant Abemaciclib Plus Endocrine Therapy in HR+/ HER2– Early Breast Cancer
Megan Kruse, MD, discusses long-term outcomes adjuvant abemaciclib with endocrine therapy in HR-positive, HER2-negative, high-risk early breast cancer.
Misako Nagasaka, MD, PhD
Misako Nagasaka, MD, PhD, is associate professor in the Division of Hematology and Oncology and the Division of Medicine at the University of California Irvine School of Medicine.
Latest:
FDA Approval Insights: Zongertinib in HER2-Mutated NSCLC: With Ticiana Leal, MD, and Misako Nagasaka, MD, PhD
Leal and Nagasaka discussed the significance of the FDA approval of zongertinib for previously treated patients with HER2 TKD–mutant advanced NSCLC.
Jason R. Westin, MD, MS, FACP
Latest:
ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma
Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.
Shira Dinner, MD
Shira Dinner, MD, is an associate professor in the Feinberg School of Medicine at Northwestern University.
Latest:
Highlighting Key ALL Updates and Data From EHA 2025
Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss key data in acute lymphoblastic leukemia presented at the 2025 EHA Congress.
Sheila Figel, PhD
Latest:
Dr. Figel on Preclinical Research With Survivin Isoforms in Cancer Cells
Sheila Figel, PhD, a neuro-oncologic scientist with Roswell Park Comprehensive Cancer Center, discusses preclinical research with canonical and noncanonical that are displayed on the surface of cancer cells.
Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath
Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, is a clinical professor of hematology, of the Faculty of Medicine & Health Sciences, at the University of Nottingham (Centre for Cancer Sciences, Academic Unit of Translational Medical Sciences, School of Medicine).
Latest:
Dr Fox on the Design of the TERZO Trial of Duvelisib in R/R Nodal T-Cell Lymphoma
Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, discusses the TERZO trial investigating duvelisib in relapsed/refractory nodal T-cell lymphoma.